You are here

NKTR-102

Breast cancer drug, key to Nektar growth plans, fails clinical trial

Breast cancer drug, key to Nektar growth plans, fails clinical trial

Bizjournals.com

Flag link:

Nektar reports positive preclinical data for two oncology programs

Nektar reports positive preclinical data for two oncology programs

The Fly on the Wall

Flag link:

Nektar presents data from Phase l study of etirinotecan pegol

Nektar presents data from Phase l study of etirinotecan pegol

Yahoo/Fly on the Wall

etirinotecan pegol

advanced cancer

Flag link:

2014 Looking Like A Big Year For Nektar

2014 Looking Like A Big Year For Nektar

Seeking Alpha

Flag link:

Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium

Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium

Yahoo/PR NewsWire

Flag link:

NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil

NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil

Yahoo/PR NewsWire

Flag link:

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting

Yahoo/PR NewsWire

topoisomerase I inhibitor

Flag link:

Nektar ovarian cancer drug gets FDA orphan status

Nektar ovarian cancer drug gets FDA orphan status

Bizjournals.com

Flag link: